

SUPPLEMENTARY MATERIALS


Real-world evidence for option value in metastatic melanoma

William B Wong, PharmD, MS; Tu My To, PhD; Meng Li, ScM, PhD; Woojung Lee, PharmD; David L Veenstra, PharmD, PhD; and Louis P Garrison Jr, PhD

Supplementary Figure 1. Study Design

Supplementary Table 1. Patient Characteristics

Supplementary Figure 1. Study Design



Supplementary Table 1. Patient Characteristics

	First Line (N=576)			Second Line (N=157)		
	First-Line Ipilimumab (any)	First-Line Chemotherapy	<i>P</i> Value ^a	Second-Line Ipilimumab + (any)	Second-Line Chemotherapy (Different Agent from First Line)	<i>P</i> Value ^b
Patients, n (%)	458 (80)	118 (20)		124 (79)	33 (21)	
Age at treatment start, years						
Mean (SD)	65.31 (12.14)	67.32 (12.25)	0.08	59.74 (13.36)	60.52 (16)	0.54
Median	68	72	NA	60	62	NA
Gender, n (%)						
Female	133 (29)	34 (29)	0.96	36(29)	11(33)	0.63
Male	325 (71)	84 (71)		88 (71)	22 (67)	
Practice type, n (%)						
Academic	59 (13)	18 (15)	0.50	18 (15)	5 (15)	0.93
Community	399 (87)	100 (85)		106 (85)	28 (85)	
Insurance, n (%)						
Any Medicaid	10 (2)	3 (3)	0.09	5 (4)	1 (3)	0.75
Commercial	66 (14)	8 (7)		17 (14)	6 (18)	
Medicare (±Commercial)	31 (7)	5 (4)		3 (2)	0 (0)	
Unknown/Missing	351 (77)	102 (86)		99 (80)	26 (79)	
Stage at advanced diagnosis, n (%)						
III	130 (28)	32 (27)	0.79	50 (40)	13 (39)	0.92
IV	328 (72)	86 (73)		74 (60)	20 (61)	
Region, n (%)						
Midwest	47 (10)	17 (14)	0.08	9 (7)	4 (12)	0.77
Northeast	72 (16)	24 (20)		21 (17)	4 (12)	
South	169 (37)	29 (25)		39 (31)	11 (33)	
West	99 (22)	25 (21)		26 (21)	7 (21)	

Unknown/Missing	71 (16)	23 (19)		29 (23)	7 (21)	
ECOG performance status, n (%)						
0–1	44 (10)	9 (8)	0.54	9 (7)	2 (6)	0.85
2+	3 (1)	0 (0)		1 (1)	0 (0)	
Missing	411 (90)	109 (92)		114 (92)	31 (94)	
Metastatic site at advanced diagnosis, n (%)						
Brain/liver/lung	250 (55)	73 (62)	0.23	57 (46)	15 (45)	0.89
Other	77 (17)	13 (11)		15 (12)	5 (15)	
None	131 (29)	32 (27)		52 (42)	13 (39)	
BRAF status, n (%)						
Negative	325 (71)	88 (75)	0.03	47 (38)	14 (42)	0.07
Positive	112 (24)	19 (16)		75 (60)	16 (48)	
Not tested	21 (5)	11 (9)		2 (2)	3 (9)	
Year of treatment start, n (%)						
2011	16 (3)	31 (26)	<0.001	6 (5)	5 (1)	0.19
2012	60 (13)	26 (22)		18 (15)	5 (15)	
2013	101 (22)	29 (25)		37 (30)	10 (30)	
2014	203 (44)	27 (23)		48 (39)	12 (36)	
2015	78 (17)	5 (4)		15 (12)	1 (3)	
Progressed/died, n (%)						
No	101 (22)	6 (5)	<0.001	2 (2)	0 (0)	0.46
Yes	357 (78)	112 (95)		122 (98)	33 (100)	

^a*P* values are a comparison between the two treatments used as first-line. ^b*P* values are a comparison between the two treatments used as second-line. Wilcoxon test or Chi-squared test statistics were used to compare differences in baseline patient characteristics by treatment group at 1L and 2L. + (any) = ipilimumab as monotherapy or in combination with other therapies; ECOG = Eastern Cooperative Oncology Group; SD = standard deviation; NA = not applicable.